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Abstract Concanavalin A (Con A) is known to trigger 
augmented secretion and proteolytic activation of the matrix 
metalloproteinases (MMPs) in fibroblasts. To study the signal-
ing pathway critical for the activation of MMPs in fibroblasts, 
we examined the effects of dominant negative ras (S17N ras) 
expression under the control of conditionally inducible promoter 
in Con A-activated 3Y1 cells. We found that augmented 
secretion and proteolytic activation of MMP-2 and MMP-9 
together with expression of MT1-MMP in Con A-activated 3Y1 
were dramatically suppressed by S17N ras expression. These 
results strongly suggest that c-Ras plays a critical role in the 
augmented expression and proteolytic activation of MMPs in 
fibroblasts. 
© 1997 Federation of European Biochemical Societies. 
Key words: Matrix metalloproteinase; MMP-2; MMP-9; 
ras; Concanavalin A; Signal transduction 
1. Introduction 
One of the critical steps for tumor invasion and metastasis 
is the destruction of extracellular matrix [1] that is catalyzed 
mainly by the matrix metalloproteinases (MMPs). MMPs are 
neutral proteinases that require Zn or Ca ions for their activ-
ity, and consist of a family including MMP-2 (gelatinase A) 
and MMP-9 (gelatinase B) [2,3]. MMPs are secreted from cells 
as inactive zymogens, and subsequently activated by proteo-
lytic cleavage [4]. A membrane-type MMP, MT1-MMP cata-
lyzes proteolytic activation of MMP-2 [5]. 
In metastatic human cancer tissues, increased secretion and 
proteolytic activation of MMPs are often observed [6]. How-
ever, a large body of evidence has been accumulated that 
MMPs including MMP-2, MMP-9, stromelysin-3 and MT1-
MMP in tumor tissues are secreted from the stromal fibro-
blastic cells rather than tumor cells themselves [7-9]. Thus, the 
regulatory mechanism of MMPs in the stromal fibroblastic 
cells of tumor is an important problem to be clarified. 
To study the signaling pathway critical for the activation of 
MMPs in fibroblasts, we examined the effects of dominant 
negative ras (S17N ras) expression in concanavalin A (Con 
A)-activated 3Y1 cells. Con A, a tetravalent lectin, is known 
to trigger augmented secretion and proteolytic activation of 
MMPs in fibroblasts, hence is widely used for the study of 
MMP activation [10,11]. Since Con A treatment of cells is 
known to activate tyrosine phosphorylation and stimulate 
phosphatidylinositol 3-kinase [12,13], it may mimic the signal-
ing mechanism that results in activation of MMPs. However, 
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the exact mechanism yet remains largely unclear. To examine 
whether c-Ras is involved in Con A-dependent signaling, we 
established a cell line in which S17N ras is conditionally ex-
pressed under the control of mouse mammary tumor virus 
(MMTV) promoter/enhancer. Expression of S17N ras, a mu-
tant ras with Asn substitution for Ser at position 17 of Ras11, 
was shown to yield a dominant inhibitory effect on endoge-
nous Ras [14]. Here, we show that expression of S17N ras in 
3Y1 inhibits both proteolytic activation and augmented secre-
tion of MMP-2 and MMP-9 in Con A-activated cells. In 
addition, we show evidence that expression of MT1-MMP 
which catalyzes activation of MMP-2 is also activated by 
Con A and inhibited by S17N Ras. Our results strongly sug-
gest that c-Ras plays a critical role in Con A-dependent sig-
naling that results in induction and activation of MMPs in 
fibroblasts. 
2. Materials and methods 
2.1. Cell culture, plasmid construction and transfection 
A rat fibroblast cell line, 3Y1, was cultured as previously reported 
[15]. S17N ras, a generous gift of Dr. L. Feig, was ligated into a vector 
pMAM2-BS'Z> (Kaken Seiyaku) which has the MMTV promoter and 
transfected into 3Y1 cells as previously described [16]. Blastocidin (10 
ug/ml)-resistant colonies were isolated and S17N Ras expressing 
clones in the presence of dexamethasone (2 uM) were selected by 
immunoblotting with anti-pan Ras antibody (Santa Cruz) as de-
scribed previously [17]. 
2.2. Con A treatment of 3Y1 
3Y1 and S17N ras-transfected 3Y1 were treated with Con A (5-20 
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Fig. 1. Induction and activation of MMP-2 and MMP-9 by Con A 
treatment. 3Y1 cells were incubated with 0 or 2 uM dexamethasone 
for 24 h, and then treated with 0, 5, 10 or 25 ug/ml of Con A for 
24 h in serum-deprived medium in the presence or absence of dexa-
methasone. Conditioned media were collected and subjected to gela-
tin zymography as described in Section 2. Arrows indicate 92- and 
68-kDa zymogen forms of MMP-9 and MMP-2, respectively; large 
arrowheads, 84- and 63-kDa active forms of MMP-9 and MMP-2, 
respectively; small arrowheads, additional gelatinases observed in 
Con A-activated cells. 
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Fig. 2. S17N Ras expression in transfected 3Y1 treated with Con A. 
S17N ras-transfected cells incubated with or without dexamethasone 
for 24 h were treated with 0, 5 or 10 ug/ml of Con A in the pres-
ence or absence of dexamethasone for an additional 24 h. Cells 
were collected and examined by immunoblotting with anti-pan Ras 
antibody. 
ug/ml) in serum-deprived medium for 24 h, and conditioned media 
were collected for zymography. 
2.3. Assay of gelatin-degrading MMPs by zymography 
The activities of MMPs in the conditioned media were assayed by 
zymography as previously described [18]. 
2.4. Western blotting 
Immunoblotting with anti-pan Ras and anti-MTl-MMP (Fuji Ya-
kuhin Kogyo) was performed as described previously [19]. 
3. Results and discussion 
We first examined the effect of Con A treatment on MMP 
secreted from 3Y1 by zymography. Without treatment, 3Y1 
cells secreted only zymogen forms of MMP-2 and MMP-9 of 
68 and 92 kDa, respectively, as judged by immunoprecipita-
tion and immunoblotting with specific antibodies (data not 
shown). We found that Con A treatment dramatically acti-
vated both secretion and proteolytic activation of MMP-2 and 
MMP-9 in a dose-dependent manner. As shown in Fig. 1, 
secretion of 68- and 92-kDa bands was elevated, and 63-
and 84-kDa bands together with additional smaller bands 
appeared by Con A treatment. As previously reported [6], 
these 63- and 84-kDa bands were active forms of MMP-2 
and MMP-9. We confirmed that treatment of 3Y1 with dex-
amethasone which was used in the following study showed no 
inhibitory effect on augmented secretion and proteolytic acti-
vation of MMPs by Con A. 
In contrast to Con A treatment, we found that only MMP-
2, but not MMP-9, was activated in H-ras transformed 3Y1. 
Gum et al. [20] reported that transformation of ovarian ad-
enocarcinoma cell line, OVCAR-3, by H-ras resulted in the 
activation of MMP-9 secretion. Although our results were not 
consonant with those of Gum et al., this may simply reflect 
the difference of cell lines used for the study. At any rate, our 
results suggest that the signaling pathway for the activation of 
MMP-9 may differ in part from that of MMP-2. 
To study the role of Ras in Con A-dependent activation of 
MMPs, we established 3Y1 cells transfected with condition-
ally inducible S17N ras. Among several clones we isolated, 
one that responded well to the dexamethasone treatment 
was used throughout the study. Under the control of 
MMTV promoter/enhancer, S17N ras was induced by treat-
ment with dexamethasone (Fig. 2). We confirmed that Con A 
treatment had no inhibitory effect on dexamethasone-depend-
ent expression of S17N ras. We found Con A treatment 
slightly activated tyrosine phosphorylation of cellular proteins 
as previously reported [12,13], but S17N ras expression has no 
clear effect on overall tyrosine phosphorylation of both un-
treated and Con A-treated cells (data not shown). 
We next examined the effect of S17N ras expression on Con 
A-dependent secretion and activation of MMPs by zymogra-
phy (Fig. 3A). Without S17N ras expression, transfected cells 
responded well to Con A treatment and showed enhanced 
secretion and proteolytic activation of both MMP-2 and 
MMP-9. In contrast, S17N ras expression by dexamethasone 
treatment dramatically suppressed both secretion and proteo-
lytic activation of MMP-2 and MMP-9. We next examined 
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Fig. 3. Effects of S17N ras expression on induction and activation of MMPs by Con A treatment. S17N raw-transfected 3Y1 cells preincubated 
with 0 or 2 uM dexamethasone for 24 h were treated with 0, 5, 10 or 25 ug/ml of Con A for 24 h in serum-deprived medium in the presence 
or absence of dexamethasone. A: After treatment, conditioned media of cells were collected and subjected to zymography. B: After treatment, 
cells were subjected to immunoblotting with anti-MTl-MMP antibody. 
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the expression of MT1-MMP that catalyzes proteolytic acti-
vation of MMP-2 by immunoblotting with anti-MTl-MMP 
(Fig. 3B). While MT1-MMP expression was strongly acti-
vated by Con A treatment in cells without dexamethasone, 
its expression was drastically suppressed by dexamethasone 
treatment. Thus, these results strongly suggest that c-Ras 
plays a critical role not only in augmented secretion and pro-
teolytic activation of MMP-2 and MMP-9 but also in expres-
sion of MT1-MMP which catalyzes MMP-2 activation. Our 
results also suggest that these MMPs share similar signaling 
pathways for their expression. 
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